GSK's Mon­cef Slaoui joins the board at Mod­er­na; Aduro pro­motes van El­sas to CSO

→  Anap­tys­Bio CSO Matthew Moyle has abrupt­ly re­signed and left the com­pa­ny. An SEC fil­ing notes he got nine months salary as sev­er­ance.

An­drea van El­sas, the chief sci­en­tif­ic of­fi­cer of Aduro Biotech Eu­rope, will be ap­point­ed chief sci­en­tif­ic of­fi­cer of the moth­er com­pa­ny Aduro Biotech in Berkley, CA.

→ Mon­cef Slaoui, the for­mer R&D and vac­cines chief at Glax­o­SmithK­line, is join­ing the board at the mR­NA com­pa­ny Mod­er­na. Slaoui is an en­thu­si­as­tic cham­pi­on of pi­o­neer­ing drug R&D. And he says he’s look­ing “for­ward to work­ing with the team to nav­i­gate this un­chart­ed ter­ri­to­ry, and sup­port the strate­gic plan­ning al­ready un­der­way as Mod­er­na works to de­liv­er mR­NA med­i­cines and vac­cines to ad­dress se­ri­ous un­met med­ical needs in the U.S. and glob­al­ly.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.